Storm Therapeutics secured a $56 million Series C to advance STC-15, its RNA enzyme inhibitor targeting myo- and liposarcomas, and reported that the first patient has been treated in a new Phase 2 program. The funding and patient dosing mark a shift from preclinical promise toward clinical evidence generation for an underexplored RNA epigenetics mechanism in solid tumors.